Sage Therapeutics (SAGE) SAGE-217 Ph3 Data 'Very Impressive' - BMO

BMO Capital analyst Gary Nachman reiterated an Outperform rating and $203 price target on Sage Therapeutics (NASDAQ: SAGE) after the company reported "very impressive" Ph3 data for SAGE-217 in PPD that demonstrated strong efficacy across the board and an overall good safety profile.

"These data for the oral formulation are consistent with what we’ve seen with Zulresso IV for PPD (PDUFA on March 19) and previous Ph2 data for SAGE-217 in MDD, and should support a significant opportunity for the product," the analyst commented.

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $97.51 yesterday.

You May Also Be Interested In

• Progressive Corp. (PGR) PT Lowered to $205 at BMO Capital
• Canaccord Starts Relay Therapeutics (RLAY) at Buy
• Schneider National (SNDR) PT Raised to $40 at Benchmark on 'Solid' Q2 Expectations